Despite concerns about startup investment overall, Biotech continues to attract VC capital. The combination of AI and biology is accelerating new treatment development
FY2024 EPS Estimates for Taysha Gene Therapies, Inc Cut by Analyst (NASDAQ:TSHA) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its target price boosted by Cantor Fitzgerald from $6.00 to $7.00 in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has an overweight rating on the stock. Several other research firms also recently issued reports on TSHA. Needham & Company LLC […]